Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

The pharma believes sugemalimab could be a best-in-class checkpoint inhibitor

The pharma believes sugemalimab could be a best-in-class checkpoint inhibitor.

A deal giving Pfizer local rights to CStone’s PD-L1 inhibitor will add at least $200 million to the Suzhou-based biotech’s balance sheet